Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events

Abstract

Introduction

Data on real-world experiences for patients treated with ixekizumab is currently limited.

Objectives

Describe characteristics of ixekizumab-treated psoriasis patients and provide evidence of clinical outcomes using disease severity scores Body Surface Area (BSA) and Psoriasis Area and Severity Index (PASI) in the real world.

Methods

Chart review was performed for adult patients treated with ixekizumab at a single Canadian dermatology clinic (February 2017–August 2018). The cohort was stratified into responders (patients who remained on ixekizumab) and non-responders (patients who discontinued ixekizumab). Subgroup analyses were performed for responders to assess clinical improvement stratified by previous biologic exposure.

Results

Thirty-eight patients were included (mean observational time 32 weeks). At baseline, mean PASI and BSA were 10.8 and 11.6%, respectively. Mean changes in PASI and BSA were –7.8 and –6.7%, respectively, at week 4. PASI 100 was achieved in 70% of patients. Significant differences in mean change of BSA were seen between bio-naïve and bio-experienced patients.

Conclusion

This analysis represents the first investigation of early clinical outcomes in a small cohort of Canadian patients treated with ixekizumab. Overall, complete and rapid skin clearance was observed. Future studies including more patients and longer follow-up time are crucial to confirm these findings.

Keywords:

• Real-world effectiveness
• ixekizumab
• rapid clearance

Ethical approval

Ethics approval for this study was obtained from the Health Research Ethics Board (#2017.230). Since this study is secondary use of data, specific patient consent for this study was waived.

Disclosure statement

Russel Burge and Sonia Montmayeur are full time employee and shareholder of Eli Lilly and Company, the study sponsor. Wayne Gulliver reports honoraria received from AbbVie, Actelion, Arylide, Celgene, Cipher, Eli Lilly, Janssen, Novartis, Tribute, and Valeant as member of advisory board; grants received from AbbVie, Amgen, Eli Lilly, Novartis, and Pfizer; study fees received (as an Investigator) from AbbVie, Astellas, Celgene, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, and Regeneron; honoraria received for speaking engagements from AbbVie, Actelion, Celgene, Janssen, Eli Lilly, LEO Pharma, Novartis, and Valeant; honoraria received for consultation from AbbVie, Amgen, Eli Lilly, Janssen, and Novartis; and honoraria received for chairing/moderating sessions from AbbVie, Eli Lilly, and Novartis outside the submitted work.

Additional information

Funding

Funding for this project was provided by Eli Lilly and Company.